• CRISPR gene editing to generate FMRP KO and CGG-deleted isogenic iPSCs 
Introduction
Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by a CGG repeat expansion in the 5'-UTR of the Fragile X mental retardation gene, FMR1 [1] . Expansions of >200 repeats can lead to hypermethylation of the CGG repeats and CpG islands in the upstream promoter region. This hypermethylation results in heterochromatin formation and silencing of the FMR1 transcript, thereby preventing FMRP protein production [2, 3] . FMRP is an RNA-binding protein [4, 5] that is highly expressed in neurons [6, 7] where it plays a key role in regulating local activitydependent synaptic translation [8] . The absence of FMRP affects both synaptic formation and maturation [9] , as well as different forms of synaptic and homeostatic plasticity [10] [11] [12] [13] . A potential manifestation of this abnormal synaptic function is increased excitability in FXS neurons [14] . For example, increased seizure susceptibility has been observed in both FXS patients [15] and Fmr1 knockout mice [16] . Moreover, studies in Fmr1 knockout mice showing aberrant ion channel expression and function [17] [18] [19] [20] , altered intrinsic neuronal properties [21, 22] and augmented network activity [22, 23] all demonstrate FMRP-dependent effects on neuronal hyperexcitability. The Fmr1 knockout mice have been a good model for understanding the signaling pathways, pathophysiology, and behavioral phenotypes associated with FXS. However, disease-modifying therapeutics from mouse models have not translated well to the clinic [24] .
FXS patient derived iPSCs represent an alternative model system to identify potential strategies for FMR1 reactivation, rather than targeting downstream pathways. FXS iPSCs retain expanded CGG repeats, promoter hypermethylation and FMR1 silencing after reprogramming [25, 26] , and have been used to demonstrate that removal of the expanded CGG repeat region leads to demethylation of the FMR1 promoter and reactivation of FMR1 [27, 28] . Additionally, recent studies have shown that removal of the CGG repeat region in FXS iPSC-derived neurons not only fully-restores FMRP levels, but also normalizes a hyperexcitable phenotype [29] , as well as rescues synaptic scaling deficits [13] . Moreover, demethylation of the extended CGG could also restore FMR1 levels and attenuate increased spontaneous activity in FXS iPSC-derived neurons [29] . While it has been demonstrated that near complete restoration of FMR1 levels was able to normalize a hyperexcitable phenotype, there has not yet been a systematic assessment to determine if partial restoration is sufficient to correct this phenotype.
In this study, we utilize two different isogenic iPSC pairs to confirm that the absence of FMRP leads to neuronal hyperactivity using multielectrode arrays (MEAs). We used orthogonal gene expression technologies to titrate the levels of FMRP expression in excitatory human neurons. We then determined the levels of FMRP necessary to correct this phenotype by two separate means: first, the proportion of FMRP positive neurons needed throughout the culture, and second, the total amount of FMRP required as a percentage of control levels. Our data demonstrates that partial restoration of FMRP is sufficient to normalize hyperactivity in FXS iPSCderived neurons.
Materials and Methods iPSC culture
WT isogenic control and FXS iPSC lines used in this study are listed in supplemental table S1. iPSCs were cultured on Geltrex (Thermo Fisher Scientific, A1413302) coated flasks in StemFlex TM medium (Thermo Fisher Scientific, A3349401) and fed with fresh media every other day. Cells were passaged using ReLeSR TM (STEMCELL Technology, 05873) and tested for mycoplasma and karyotypic abnormalties. iPSCs were cryopreserved in CryoStem™ hPSC Freezing Medium (Biological industries, 05-710-1E). To recover the iPSCs, vials were thawed in a 37°C water bath for 2 min until a small piece of ice was left in the vial. 1 mL thawing media (StemFlex with 1x RevitaCell (Thermo Fisher Scientific, A2644501)) was added dropwise, then transferred to a 50 mL conical containing 10mL thawing media. Cryovials were rinsed once with 1 mL thaw media. Cells were spun at 200 g for 5 min at room temperature, and the supernatant aspirated. Cells were resuspended in 10 mL thawing media and plated.
FMR1 KO isogenic iPSC engineering
To generate FMR1 KO iPSCs, Epi49 WT iPSCs (Thermo Fisher Scientific, A18945) were cultured in Geltrex coated T75 flask. The day before electroporation, cells were fed with fresh Stemflex TM medium with 1X RevitaCell supplements. Cells were dissociated with 5 ml Accutase TM cell dissociation reagent (STEMCELL technology, 07920). After washing once with PBS, cells were resuspended in Resuspension buffer R (Neon TM Transfection System 100μL Kit, Invitrogen, 10431915) to a final cell density ~ 10 8 /mL. Transfer 60 ug Cas9-2A-GFP-FMR1 gRNA plasmid (with the gRNA sequence 5'-TATTATAACCTACAGGAGGT-3' targeting against exon 3) into the dissociated iPSCs and electroporate with the following program: Pulse voltage 1,100V; Pulse width 30ms; Pulse number 1; Cell density at 1 x 10 8 cells/mL. After electroporation, cells were plated into a Geltrex coated T75 flask using Stemflex TM medium with 1 X RevitaCell supplements. On day 3 post electroporation, cells were dissociated with Accutase for FACS sorting to enrich the GFP+ population, and re-plated onto Geltrex coated 10cm Petri dish at ~ 5,000 cells/plate. 1X RevitaCell was supplemented in the Stemflex medium to enhance the cell viability. iPSC cell colonies were hand-picked and expanded in Stemflex medium from 96 wells to 12 wells, and further expanded for cryopreservation. Two primers HW15 (5'-actatattgccgttatgtcccactcag-3') and HW16 (5'-taagatgagttagtcaaaagcacgtgtc-3') were used to generate the PCR amplicon that flanks the gRNA target region in exon 3 of FMR1. Based on sequencing results, clone A2 has homozygous frameshift mutation leading to a premature stop codon for FMRP protein with the following truncated peptide sequence MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFRL*. (Figure 6A) Neuronal differentiation of iPSC NGN2 neurons were derived from human WT and FXS iPSCs according to a modified method described by Zhang et al. (Zhang et al, Neuron, 2013) . Briefly, WT and FXS iPS cells were cultured on Geltrex in StemFlex™ medium, and dissociated with TrypLE™ (Thermo Fisher, 12605010) as single cells. Cells were infected with pTet-O-NGN2-2A-Puro virus (1 x 10 9 IFU/mL) in suspension at MOI ~ 5 and plated in Stemflex with 1X RevitaCell. Infected cells were cultured and expanded on Geltrex in StemFlex media. On differentiation day 0, cells were dissociated with TrypLE™ and replated in StemFlex with RevitaCell and 2 μg/mL Doxycycline (Fisher Scientific, BP2653-1) to induce TetO gene expression. Media was changed 24hrs post induction to DMEM/F12 (Thermo Fisher, 11320033) with 1X N2 supplement (Thermo Fisher, 17502048), 1X Glutamax (Thermo Fisher, 35050061), 0.3% D-(+)Glucose (Sigma Aldrich, G8769), 2 μg/mL Doxycycline and 3.34 μg/mL Puromycin (Thermo Fisher, A1113808) to start selection. 48 h post-induction, the media was changed to differentiation media containing 1X B27 supplement (ThermoFisher, 17504044). Neurons were dissociated on day 3 with room temperature StemPro™ Accutase™ Cell Dissociation Reagent (Thermo Fisher, A1110501) and re-plated into PDL and Laminin (Thermo Fisher, 23017-015) coated plates in NBM media (Neurobasal™ Media (ThermoFisher, 21103049) with 1X MEM NEAA (Thermo Fisher, 11140050), 1X Glutamax, 0.3% D-(+)-Glucose, 2 μg/mL Doxycycline, 3.34 μg/mL Puromycin, 1X B27 supplement, and 10 ng/mL rhBDNF (R&D Systems, 248-BDB/CF)) and rhGDNF (R&D Systems, 212-GD)). The day following plating, fresh NBM was added to the cultures. Half media changes were conducted weekly.
qRT-PCR
Cells were lysed using Real-Time ready cell lysis buffer (Roche Life Science, 7248431001) with 1:80 diluted RNAse inhibitor (Sigma, 3335402001) and DNAseI (ThermoFisher Scientific, AM2222). 96-well plates were lysed by aspirating the media the cells and adding 50 μL lysis buffer per well. The plates were shaken at 1250 RPM for 25 min. The lysate was mixed with a pipette 10 times and checked for lysis under the microscope. Plates were frozen for at least 15 min at -80°C. Lysates were thawed on ice and diluted 1:5 with nuclease-free water. 2.25 μL of diluted total lysate was used in a PreAmp reaction with the FMR1-FAM and POP4-ABY TaqMan assays (5 μL PreAmp Master Mix (Applied Biosystems 4488593), 2.5 μL 0.2X diluted FMR1 and POP4 assays, 0.25 μL 40X TaqMan RT enzyme mix (Applied Biosystems A36107C), 2.25 μL lysate). The preamp reaction was run for 12 cycles in an Applied Biosystems QS7 machine. PreAmp reactions were diluted 1:5 and 2 μL used in a qPCR reaction with the same two TaqMan assays (5uL TaqMan Fast Advanced Master Mix (Applied Biosystems 4444557), 0.5 μL 20X FMR1-FAM TaqMan assay, 0.5 μL 20x POP4-ABY TaqMan assay, 2 μL Nuclease-Free water) and run on a QuantStudio 7 (Thermo Fisher Scientific).
Immunofluorescence and imaging analysis
Neurons were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature. Cells were permeabilized with PBST (1X PBS solution with 0.5% Triton X-100) before blocking with 5% BSA in PBST. Cells were then incubated with appropriately diluted primary antibodies in PBST with 1% BSA for 1 h at room temperature or overnight at 4°C. After washing with PBST for 3 X 10 min at room temperature, cells were incubated with fluorophore labeled secondary antibodies and DAPI. Cells were washed three times with PBST at room temperature and subjected to imaging using CellInsight CX7 High-Content Screening (HCS) Platform (Thermo Fisher Scientific). Data were analyzed using Cellomics software and plotted with Prism GraphPad for statistical analysis. For imaging-based quantification, unless otherwise specified, >10 representative images were quantified, and data were plotted as mean±SD. Dilution for antibodies used in this study is listed in supplemental table 3.
MEA and data analysis
48 well multielectrode array plates containing an array 16 embedded gold electrodes were used for all MEA experiments (Cat. #M768-KAP; Axion BioSystems, Atlanta, GA). The day before cell plating, MEA wells were coated with a 0.07% polyethylenimine (PEI) solution (Sigma, St. Louis, MO) for 2 h in a 37°C cell-culture incubator. Plates were rinsed with sterile, deionized water four times and air dried in a biological safety cabinet overnight. Neurons were cultured in BrainPhys medium (STEMCELL Technology) supplemented with 1X N-2 Supplement (ThermoFisher), 1 μg/mL Laminin (Sigma-Aldrich), Neural Supplement B (Cellular Dynamics, M1029), Nervous System Supplement (Cellular Dynamics, M1031), and 1X Penicillin-Streptomycin (ThermoFisher). On the day of plating, a 10µL drop of complete BrainPhys media containing 80 μg/mL Laminin was placed directly in the center of each well over the MEA electrodes. The plates were then incubated for at least 1 h at 37°C. A 10µL drop of cell suspension was then plating directly into the 10µL drop of complete BrainPhys media containing 80 μg/mL Laminin, for a final volume of 20µL and final density of 75,000 neurons per well. The cells were allowed to attach to the substrate in a cell-culture incubator for 1 h, and then 500 μL culture medium was added to the wells. Cells were grown at 37°C in a humidified 5% CO2/95% O2 incubator. To maintain the culture, a 50% medium change with fresh 37°C culture medium was performed every 3-4 days.
Spontaneous neuronal activity, including burst rate and firing rate, were recorded every day using the Axion Maestro MEA platform (Axion Biosystems). Recording was performed every day before or after dCas9-Tet1/CGG sgRNA, FMR1 mRNA and FMR1 ASO treatments. Data were analyzed using a custom MATLAB program [30] and presented as mean ± SD, and are considered statistically significant when p < 0.05 by paired Student's T-Test or one-way ANOVA, where appropriate.
FMR1 mRNA Transfection
FMR1 mRNA was designed with full substitution of pseudo-U and ARCA capped to enhance the stability and translation efficiency. The mRNA was synthesized by TriLink BioTechnologies (L-6009) and purified with Silica membrane with enzymatical polyadenylation and Dnase treatment. mRNA transfection was performed using Lipofectamine™ MessengerMAX™ Transfection Reagent (ThermoFisher Scientific, LMRNA003) according to manufacturer's instruction. Briefly for transfection of each well, various amounts of mRNAs were diluted in 15 μl OptiMEM and combine with prediluted 15 μl 2X Lipofectamine MessengerMAX reagent (0.5 μl/well) in equal volume of OptiMEM. Transfectant were fully mixed by vortexing and incubation at RT for 5 min. 30 μl transfection cocktail were added into each well of the neuronal culture for transfection. Change 75% of the media 16 h after transfection. A synthetic CleanCap™ EGFP mRNA (TriLink, L-7201) was used as a transfection positive control in this study.
dCas9-Tet1 construct and lentiviral transduction
The Fuw-dCas9-Tet1CD-P2A-BFP (Addgene, 108245), Fuw-dCas9-dTet1CD-P2A-BFP (Addgene, 108246) and CGG sgRNA-mCherry co-expression plasmids were gifts from Rudolf Jaenisch lab at Whitehead Institute, MIT, Cambridge, MA. The FMR1 CGG sgRNA expression construct was cloned by inserting annealed oligos into modified pgRNA plasmid (Addgene plasmid: 44248) with AarI site. To package lentivirus, a synthetic gene block encoding the bacteriophage AcrIIA4 purchased from IDT was cloned into a modified FUW vector [29] . All constructs were sequenced before lentiviral packaging and production at 1 x 10 9 IFU/mL by Alstem LLC. For lentiviral transduction, neurons were infected with combination of dCas9-Tet1CD/CGG sgRNA and dCas9-dTet1CD/CGG sgRNA at various MOI, media were changed 16 h post transduction. 
FMR1 ASO treatment

Results
Quantification of FMRP-expression in isogenic pair of iPSC-derived neurons
In this study, we utilized an isogenic pair of iPSCs in which the expression level of FMRP was the differentiating variable. This pair was generated by identifying clonal lines following CRISPRmediated removal of the CGG-repeat region from the FMR1 gene of a human FXS iPSC line harboring a >450 CGG repeat expansion [27] . We have previously confirmed both the lack of FMR1 expression and increased spontaneous activity in these FXS iPSC-derived cortical excitatory neurons as compared to CRISPR-edited isogenic control [29] . Figure 1A shows representative immunofluorescent images from both the FXS iPSC-derived neurons (SW_FXS) and isogenic control neurons (SW_C1_2) demonstrating robust FMRP staining in cell bodies of control neurons compared to no FMRP staining in the FXS iPSC-derived neurons. Figure 1A also demonstrates that both cell lines display multiple neuronal markers such as β-Tubulin, MAP2 and NeuN. FMRP levels are quantified in Figure 1B by the percentage of FMRP+ neurons, with close to 80% of C1_2 neurons positive for FMRP, and around 1% of FXS neurons positive for FMRP (C1_2: 79.2±15.4%, n=18 wells; FXS: 1.2±1.3%, n=24 wells).
Absence of FMRP results in increased spontaneous activity
To confirm published work demonstrating increased spontaneous activity in excitatory FXS iPSCderived neurons, we compared the levels of spontaneous electrical activity for both isogenic lines using multi-well MEA plates. The level of spontaneous activity was quantified using an average weighted firing rate per well, which was calculated as a product of the spontaneous spikes per minute and the number of active electrodes in the well. Figure 1C shows the spontaneous activity for all three isogenic pairs of iPSC-derived neurons over the course of seven weeks. These data demonstrate that neurons lacking FMRP expression begin to show increased spontaneous activity after 3 weeks which is maintained throughout the remaining time in culture. Cumulative data from the fourth week shows a significantly higher weighted firing rate for FXS iPSC-derived neurons when compared to the corrected isogenic control (FXS: 760.5±918.0, n=120 wells, C1_2: 406.0±254.6, n=118 wells, *p<0.01, two-way ANOVA, Sidak's multiple comparison test).
Mixed neuronal culture determines the level of FMRP mosaicism for functional restoration
We next sought to determine how many FMRP positive neurons would be needed to normalize the increased spontaneous activity seen in FXS neuronal cultures. To do this, we generated mixed cultures of FMRP-expressing (C1_2) and FMRP-non-expressing (FXS) neurons by titrating specific ratios of C1_2 neurons into FXS cultures. This paradigm allowed for the generation of a panel of FMRP mixed cultures that mimic neuronal environments in FXS mosaic male patients and female carriers. Figure 2A shows representative images of from 100% C1_2 and 100% FXS neuronal cultures, along with FXS cultures in which 1% and 20% C1_2 neurons have been mixed with 99% and 80% FXS neurons respectively. The percentage of C1_2 neurons for each of these mixed cultures is quantified by ICC in Figure 2B , showing increasing amounts of FMRP positive neurons as the ratio of C1_2 to FXS neurons is increased. When the level of spontaneous activity was measured for the different mixed-ratio cultures, a significant increase in spontaneous activity was seen in 100% FXS cultures as compared to 100% C1_2 (100% C1_2: Figure 3A .
The lower two panels demonstrate the stochastic nature of FMRP expression 24hr post transfection in which neurons are either FMRP positive or FMRP negative, with the number of FMRP-expressing neurons dependent upon the amount of transfected FMR1 mRNA. The percentage of FMRP-expressing neurons is quantified in Figure 3B , showing that as the amount of FMR1 mRNA is increased, the percentage of FMRP+ neurons also increases, with a maximal level of around 25% FMRP positive neurons achieved 24h after transfecting. This FMRP expression at 24h represented the peak expression levels, with levels beginning to decrease 48-72h later. Due to the transient nature of FMRP expression following FMR1 mRNA transfection, the greatest effect on spontaneous activity was seen 24-32h post transfection ( Figure 3C ). Here, the data from 3 recording sessions at 24h, 28h and 32h post-transfection were averaged and normalized to a pre-transfection baseline recording. From this data, a significant difference in spontaneous activity between C1_2 and FXS is seen during this post-transfection time period. In addition, only FXS cultures that were transfected with 24ng of FMR1 mRNA demonstrated a significant reduction in spontaneous activity compared to the mock treated FXS neuronal cultures (FXS: 2.5±2.2, n=123; FXS + 24ng FMR1 mRNA: 1.6±2.8, n=153, *p<0.05, one-way ANOVA, Dunnett's multiple comparison test). This level of FMR1 mRNA corresponded to 24.6±5.5% FMRP-positive neurons (n=6 wells). These data support the conclusion that greater than 20% FMRP-expressing neurons normalize the increased spontaneous activity seen in FXS cortical neuronal cultures.
Titration of FMR1 ASO leads to varying reduced levels of FMRP reduction in WT neurons results in increased spontaneous activity
After establishing that greater than 20% FMRP-expressing neurons were needed to normalize the increased spontaneous activity seen in FXS cultures, we next sought to determine the overall expression levels of FMRP, rather than the number of highly-expressing FMRP neurons, that are required to normalize FXS spontaneous activity. To achieve this, we first attempted to uniformly lower FMR1 levels across the culture using antisense oligonucleotides (ASOs) targeted to the FMR1 mRNA in C1_2 neurons (Figure 4 ). Figure 4A demonstrates the level of both FMR1 and FMRP following a 2wk treatment with two different FMR1-targeting ASOs. Here, a robust knockdown of FMR1 is seen following treatment with both ASOs at 1 µM (ASO #1: 28.8±1.8% of control, n= 3; ASO #2: 26.6±2.8% of control, n= 3). An even greater reduction in FMRP was observed following ASO treatment, with ASO #1 producing around a 93% reduction in FMRP and ASO #2 producing around a 96% reduction (ASO #1: 7.0±0.5% of control, n= 3; ASO #2: 4.4±2.0% of control, n= 3). When the spontaneous activity of C1_2 cultures was recorded 2 weeks post-ASO treatment, only cultures treated with 1µM ASO #2 showed a significant increase in spontaneous activity as compared to C1_2 cultures treated with a non-targeting control ASO. Cultures treated with 1µM ASO #1 did not show a significant increase in spontaneous activity, suggesting that 7% FMRP expression within the culture was sufficient to prevent the increased spontaneous activity, whereas the 4% FMRP expression produced with 1µM ASO #2 was a great enough reduction to induce increase spontaneous activity ( Figure 4B ; C1_2 + 1µM Control ASO: 57.0±50.0, n=21; C1_2 + 1µM ASO #1: 90.8±92.5, n=9; C1_2 + 1µM ASO #2: 241.4±188.8, n=12; *p<0.05, one-way ANOVA, Dunnett's multiple comparison test). These data suggest that while greater than 20% FMRP-expressing neurons are needed to normalize increased spontaneous activity in FMRP mosaic cultures, a lower level of FMRP expression across all neurons in a culture may be enough to normalize increased spontaneous activity due to the absence of FMRP.
Titration of dCas9-Tet1/CGG sgRNA leads to increasing levels of FMRP in FXS neurons and functional rescue
In addition to knocking down FMRP in FMRP-expressing C1_2 neurons, we also attempted to reactivate FMRP in FXS neurons. To this end, we utilized a catalytically-inactive Cas9 protein fused to the methylcytosine dioxygenase Tet1 as targeted DNA demethylation editing machinery. We have previously shown that this construct, when targeted to the CGG-repeat region of the FMR1 gene, can demethylate this hypermethylated region and reactivate FMR1, resulting in FMRP expression in multiple FXS iPSCs and neurons [29] . Here, we transduced iPSC-derived FXS neurons with low titers of the dCas9-Tet1 construct to produce partial reactivation of FMR1 ( Figure 5 ). Figure 5A depicts representative images from FXS, C1_2 and FXS neurons transduced with 1 MOI of the dCas9-Tet1 construct. These images show no FMRP expression in the FXS neurons, robust FMRP expression in the C1_2 neurons, and low expression of FMRP in the majority of FXS neurons following transduction with dCas9-Tet1/CGG gRNA lentiviruses at 1 MOI. The quantification of FMRP intensity, normalized to C1_2 is shown in Figure 5B . . These data indicate that >7% FMRP levels is sufficient to normalize increased spontaneous activity in FXS neurons -a similar threshold level identified through our FMR1 ASO experiments in FMRP expressing C1_2 neurons in which greater than 95% FMRP reduction (or <5% FMRP levels) was needed to induce an increased spontaneous activity phenotype.
Confirmation of neuronal hyperactivity phenotype in genetically engineered FMRP KO neurons
Finally, we utilized a commercially-available healthy, normal iPSC line to create a second pair of isogenic iPSC-derived neurons that either did or did not have detectable levels of FMRP. Here, a FMR1 knockout line (FMRP KO) was created by inserting a premature stop codon in the third exon of the FMR1 gene, which resulted in normal levels of truncated FMR1 mRNA but no expression of FMRP ( Figure 6A ). Representative immunofluorescent images for this pair of isogenic iPSC-derived neurons are shown in Figure 6B . In addition, electrical activity recorded from these lines demonstrated an increased spontaneous activity phenotype in FMRP KO neurons that developed after 3 weeks in culture as compared to wild-type (WT), a similar timeframe seen with the first pair of isogenic neurons we profiled ( Figure 6C ; FMRP KO: 418.2±427.9, n=21 wells, WT: 120.1±123.4, n=15 wells, *p<0.01, two-way ANOVA, Sidak's multiple comparison test). Moreover, similar results were obtained when we performed a cell mixing experiment in which WT neurons were titrated into a culture of FMRP KO cells. These results are quantified in Figure 6D showing increasing amounts of FMRP-positive neurons as an increasing percentage of FMRP-expression control neurons are titrated into FMRP KO cultures. A statistically-significant increase in FMRP positive neurons is seen in both 80% FMRP KO / 20% Control (36.6±18.3%, n=6 wells; *p<0.01, one-way ANOVA, Dunnett's multiple comparison test) and 50% FMRP KO / 50% Control (53.2±24.8%, n=6 wells; *p<0.01, one-way ANOVA, Dunnett's multiple comparison test). When spontaneous activity levels were recorded from these cultures, only cultures with 20% or greater FMRP-expressing neurons show a significant reduction in spontaneous activity levels as compared to the 100% FMRP KO neurons ( Figure 6E ; 100% control: 1.0±0.6, n=32 wells; 100% FMRP KO: 1.8±1.1, n=31 wells; 80% FMRP KO / 20% control: 0.9±0.3, n=12 wells; 50% FMRP KO / 50% control: 1.0±0.5, n=12 wells; *p<0.05, one-way ANOVA, Dunnett's multiple comparison test). These data support an FMRP-dependent increased spontaneous activity phenotype, as well as confirm a threshold level of >20% FMRP-expressing neurons needed in a FMRP mosaic culture to normalize increased spontaneous neuronal activity.
Discussion
In this study, we have confirmed previous reports of increased spontaneous activity in FXS patient-derived excitatory neurons differentiated from iPSCs using two isogenic pairs of cell lines in which the presence or absence of FMRP is the dependent variable. In addition, we have demonstrated that this increased neuronal activity can be normalized through partial restoration of FMRP-expressing neurons within the neuronal network. Our results suggest that the number of FMRP-expressing neurons within mosaic cultures in which neurons are either expressing FMRP or not, needs to be greater than 20% in order to normalize the increased spontaneous activity. In addition, our results suggest that the overall level of FMRP expression throughout all neurons within the culture needs to be greater than 5% of normal FMRP levels in order to restore the level of spontaneous activity to control levels. These data help to provide threshold levels for potential therapeutics aimed at either fully reactivating FMR1 in a subset of neurons or partiallyreactivating FMR1 across large neuronal populations.
We utilized two different paradigms to generate FMRP mosaicism in our iPSC-derived neuronal cultures -titrating varying percentages of FMRP-expressing neurons into FXS cultures and transiently transfecting FXS neurons with different amounts of FMR1 mRNA. These FMRP mosaic cultures were composed of different percentages of FMRP positive neurons. Based on these experiments, our data suggest that greater than 20% FMRP positive neurons are needed to normalize increased spontaneous neuronal activity. This number is slightly lower than previously reported percentages of FMRP positive lymphocytes in FXS patients needed for predicting mental retardation. These cut-off levels have been reported to range between 28 and 50% [31] [32] [33] [34] . Additionally, a case report has been described in which a FXS patient with 22% FMRP positive leukocytes presented with normal physical features and a high-functioning status, compared to his fully affected brother with a typical FXS presentation and no detectable FMRP [35] . Another study that analyzed FMRP expression in both peripheral blood cells and primary fibroblasts from full mutation and mosaic FXS patients concluded that low, but non-zero expression of FMRP may be sufficient to impact cognitive function [36] . It should be noted that these studies were evaluating FMRP expression in peripheral cells, not in neurons, in which FMRP levels may not correlate. Additionally, there are multiple reports that relate the percentage of FMRP-positive hair follicles -which, like brain tissue, also originate from the ectoderm during embryonic development -to cognitive function, whereas the percentage of FMRP-positive lymphocytes does not [37, 38] . These clinical reports support the hypothesis that partial restoration of FMRP may be sufficient to normalize the FXS phenotype, and that low level neuronal FMRP reactivation throughout the brain can positively impact FXS patients. Our study is the first to demonstrate that mixed FMRP cell cultures models can recapitulate the mosaicism observed in some FXS patients, in that similar partial FMRP expression may be sufficient to normalize neuronal activity in the disease.
The use of patient iPSC-derived neurons as a physiologically-relevant model of CNS disease, in conjunction with genome editing techniques to generate isogenic controls, has revolutionized the ability to model the effects of specific disease mutations in a dish [39] . This especially holds promise for therapeutic approaches in FXS that are focused on reactivation of FMR1 as a diseasemodifying strategy. Currently, there are no animal models of FXS that allow for investigating mechanisms of FMR1 reactivation. The most widely-used model, the Fmr1 KO mouse, cannot be used to probe potential approaches targeting the root cause of the disease due to the absence of the Fmr1 gene rather than its inactivation. In addition, attempts to knock-in CGG-repeat expansions in the mouse have not resulted in hypermethylation of the repeat region and silencing of Fmr1 [40, 41] . Therefore, since FXS patient iPSCs retain expanded CGG repeats, promoter hypermethylation and FMR1 silencing after reprogramming [25, 26] , they represent an attractive disease-relevant model for investigating potential mechanisms for reactivating FMR1. Indeed, proof of concept studies showing reactivation of FMR1 in FXS-derived iPSCs and differentiated neurons have been demonstrated [27, 28] . Additionally, several groups are now using FXS patient ESCs and iPSCs to model functional effects in induced FXS human neurons [13, 29, [42] [43] [44] that can be corrected with fully-restored FMRP levels via either CRISPR/Cas9-mediated removal of the CGG repeat region [13, 29] or demethylation of the CGG repeat region [29] .
The above-mentioned studies have laid the groundwork for demonstrating that FXS functional phenotypes can be corrected in vitro. Our study is the first to attempt to understand the minimal levels of FMRP needed to normalize a specific functional phenotype -spontaneous network activity using MEAs. As such, potential small molecule therapeutics targeting FMR1 reactivation should aim to reach a critical threshold level of FMRP expression in order increase the likelihood of disease modification in patients. Several small molecule therapeutics have failed in the clinic to address various FXS symptoms [24] . We investigated the ability of some these compounds, along with other compounds that have been shown to reactivate FMR1 in non-neuronal cells [45] [46] [47] , to increase the expression of FMR1 in our iPSC-derived patient neurons. Our results however showed that we were unable to demonstrate significant reactivation of FMR1 following a threeweek treatment with any of the compounds tested (supplemental table 4). The inability of these drugs to address the root cause of the disease, along with the poor translatability of the fmr1 KO mouse model, could have contributed to their lack of efficacy. Future studies should also determine if this threshold level of FMRP is consistent across multiple patient lines with different CGG repeat expansions and methylation statuses, as well as to elucidate the levels of FMRP required to correct other functional deficits such as synaptic scaling.
In summary, we have demonstrated an FMRP-dependent neuronal phenotype of increased spontaneous activity in FXS iPSC-derived neurons that can be normalized through partial restoration of FMRP. Our data suggest that either greater than 20% FMRP-expressing neurons in a mosaic population, or greater than 5% overall FMRP expression levels throughout a neuronal network can be used as thresholds for evaluating potential therapeutic interventions focused on reactivating FMRP in iPSC-derived neurons from FXS patients. 
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